Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

October 09, 2015 12:54 PM ET


Company Overview of Horizon Pharma USA, Inc.

Company Overview

Horizon Pharma USA, Inc. is a biopharmaceutical company that develops prescription drugs for mild to moderate pain relief and arthritis. The company's products include HZT-501, a proprietary fixed dose combination formulation of NSAID and ibuprofen; and HZT-602, a combination oral drug product consisting of naproxen and famotidine. Horizon Pharma USA, Inc. was formerly known as Horizon Therapeutics, Inc. and changed its name to Horizon Pharma USA, Inc. in April 2010. The company was founded in 2005 and is based in Deerfield, Illinois. Horizon Pharma USA, Inc. operates as a subsidiary of Horizon Pharma plc.

520 Lake Cook Road

Suite 520

Deerfield, IL 60015

United States

Founded in 2005





Key Executives for Horizon Pharma USA, Inc.

Executive Vice President, Development and Regulatory Affairs and Chief Medical Officer
Age: 60
Compensation as of Fiscal Year 2015.

Horizon Pharma USA, Inc. Key Developments

Horizon Pharma plc Proposes Private Offering of Senior Notes and Intention to Enter into New Term Loan Facility

Horizon Pharma plc announced that Horizon Pharma Financing Inc. to offer $300 million aggregate principal amount of senior notes due 2023, and that Horizon Pharma Inc. intends to enter into a new term loan facility in an aggregate principal amount of $500 million. Horizon currently expects to use the net proceeds from the offering of notes and borrowings under the new term loan facility to fund a portion of Horizon's planned acquisition of Hyperion Therapeutics Inc., repay the outstanding amounts under Horizon's existing $300 million credit facility and certain outstanding debt of Hyperion, and pay any prepayment premiums, fees and expenses in connection with the foregoing. The proceeds from the offering of the notes will be held in escrow pending release in connection with the closing of the Hyperion acquisition. The notes will be offered only to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended and to non-U.S. buyers in accordance with Regulation S under the Securities Act.

Similar Private Companies By Industry

Company Name Region
Astellas US, LLC United States
Ameditech, Inc. United States
US WorldMeds, LLC United States
Troy Manufacturing Inc. United States
Endo Finco Inc. United States

Recent Private Companies Transactions

July 7, 2015
DepoMed Inc.
March 30, 2015
Hyperion Therapeutics, Inc.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Horizon Pharma USA, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at